Dipeptyl peptidase type 4 inhibitors for modern therapy of type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Over the last few decades of the last century; therapy for type 2 diabetes mellitus (DM2) was represented by sulfonylureas; biguanides and insulin drugs. Glinides; thiazolidinediones and acarbose were used much less frequently. Only since 2005 drugs whose action is based on the effects of incretins entered clinical practice. The introduction of these drugs into clinical practice has made it possible to qualitatively improve the safety parameters of glucose-lowering therapy in terms of the risk of developing hypoglycemic conditions; while maintaining high glucose-lowering activity. Dipeptyl peptidase type 4 inhibitors (DPP-4) as one of the classes of glucose-lowering drugs (GLDs) with effect on incretin mechanisms; currently occupy one of the leading places among modern GLDs. Sitagliptin and vildagliptin are prominent representatives of the DPP-4 class with a long history of use and a convincing evidence base for the effectiveness and safety of use both in monotherapy and in combinations with other classes of GLDs; incl. insulin preparations. Citadiab® (sitagliptin) and Agarta® (vildagliptin) produced by Gedeon Richter Pharma can be the drugs of choice for a significant proportion of DM2 patients in various clinical situations.

Full Text

Restricted Access

About the authors

Nikolay A. Demidov

Shcherbinka City Hospital of the Moscow Healthcare Department

Author for correspondence.
Email: nicolay13@mail.ru
ORCID iD: 0000-0001-8289-0032

Cand. Sci. (Med.)

Russian Federation, Shcherbinka

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова; М.В. Шестаковой; А.Ю. Майорова. 11-й выпуск. М.; 2023. [Algorithms for specialized medical care for patients with diabetes mellitus. Ed. by I.I. Dedov; M.V. Shestakova; A.Yu. Mayorov. 11th issue. M.; 2023. (In Russ.)]. doi: 10.14341/DM13042.
  2. Анциферов М.Б.; Демидов Н.А.; Калашникова М.Ф. и др. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом; проживающих в Москве (2013–2018). Сахарный диабет. 2020;23(2):113–24. doi: 10.14341/DM11374. [Antsiferov M.B.; Demidov N.A.; Kalashnikova M.F.; et al. The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018). Diab Mellit. 2020;23(2):113–24. (In Russ.)].
  3. Nissen S.E.; Wolski K. Effect of roziglitazone jn the risk of myocardial infarction and death from the cardiovascular causes. N Engl J Med. 2007;236:2457–71.
  4. Дедов И.И.; Шестакова М.В.; Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность; заболеваемость; смертность; параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета; статус 2017 г. Сахарный диабет. 2018;21(3):144–159. [Dedov I.I.; Shestakova M.V.; Vikulova O.K.; et al. Diabetes mellitus in Russian Federation: prevalence; morbidity; mortality; parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register; status 2017. Diab Mellit. 2018;21(3):144–59. (In Russ.)]. doi: 10.14341/DM9686.
  5. Kim W.; Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512. doi: 10.1124/pr.108.0006047.
  6. Schwartz S.S.; Epstein S.; Corkey B.E.; et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the beta-Cell-Centric Classification Schema. Diab Care. 2016;39(2):179–86. doi: 10.2337/dc15-1585.
  7. Schwartz S.S.; Epstein S.; Corkey B.E.; et al. A Unified Pathophysiological Construct of Diabetes and its Complications. Trends Endocrinol Metab. 2017;28(9):645–55. doi: 10.1016/j.tem.2017.05.005.
  8. Deacon C.F.; Ahren B. Physiology of incretins in health and disease. Rev Diab Stud. 2011;8(3):293–306. doi: 10.1900/RDS.2011.8.293.
  9. Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diab Metab. 2013;39(3):195–201. doi: 10.1016/j.diabet.2013.03.001.
  10. Yabe D.; Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107(2):248–56. doi: 10.1016/j.pbiomolbio.2011.07.010.
  11. Ahren B.; Simonsson E.; Larsson H.; et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diab. Care. 2002;25(5):869–75. doi: 10.2337/diacare.25.5.869.
  12. Green J.B.; Bethel M.A.; Armstrong P.W.; et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–42. doi: 10.1056/NEJMoa1501352.
  13. Scirica B.M.; Braunwald E.; Raz I.; et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure; saxagliptin; and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized triaL. Circulation. 2014;130:1579–88. doi: 10.1161/CIRCULATIONAHA.114.010389.
  14. Rosenstock J.; Perkovic V.; Johansen O.E.; et al. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269.
  15. McGuire D.K.; Alexander J.H.; Johansen O.E.; et al. CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019;139(3):351–61. doi: 10.1161/CIRCULATIONAHA.118.038352.
  16. Zannad F.; Cannon C.P.; Cushman W.C.B.; et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre; randomised; double-blind trial. Lancet. 2015;385(9982):2067–76. doi: 10.1016/S0140-6736 (14) 62225-X.
  17. Bekiari E.; Rizava C.; Athanasiadou E.; et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016;52(3):458–80. doi: 10.1007/s12020-015-0841-1.
  18. Kaneko M.; Narukawa M. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors; Saxagliptin; Alogliptin; and Sitagliptin in Patients With Type 2 Diabetes; Using an Alternative Measure to the Hazard Ratio. Ann. Pharmacother. 2017;51(7):570–6. doi: 10.1177/1060028017698496.
  19. Liu D.; Jin B.; Chen W.; Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC. Pharmacol. Toxicol. 2019;20(1):15. doi: 10.1186/s40360-019-0293-y.
  20. Zinman B.; Wanner C.; Lachin J.M.; et al. Empagliflozin; Cardiovascular Outcomes; and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720.
  21. Marso S.P.; Daniels G.H.; Brown-Frandsen K.; et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. doi: 10.1056/NEJMoa1603827.
  22. American Diabetes Association. Diabetes Care. 2023;46(Suppl. 1):S1–298.
  23. Викулова О.К.; Железнякова А.В.; Исаков М.А. и др. Структура сахароснижающей терапии у пациентов с сахарным диабетом 2 типа в Российской Федерации в 2017-2021 гг. В кн.: Сборник тезисов IX (XXVIII) Национального диабетологического конгресса с международным участием «Сахарный диабет и ожирение – неинфекционные междисциплинарные пандемии XXI века»; 5–8 сентября 2022 г. М.; 2022. [Vikulova O.K.; Zheleznyakova A.V.; Isakov M.A. et al. Structure of hypoglycemic therapy in patients with type 2 diabetes mellitus in the Russian Federation in 2017–2021. In: Conference Proceedings IX (XXVIII) National Diabetology Congress with international participation “Diabetes mellitus and obesity non-communicable interdisciplinary pandemics of the XXI century”; September 5–8; 2022. M.; 2022. (In Russ.)].
  24. Matthews D.R.; Paldanius P.M.; Proot P.; et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year; multicentre; randomised; double-blind trial. Lancet. 2019;394(10208):1519–29. doi: 10.1016/S0140-6736(19)32131-2.
  25. Демидов Н.А.; Калашникова М.Ф.; Пашкова Е.Ю.; Анциферов М.Б. Особенности ведения пациентов с сахарным диабетом 2 типа старше 85 лет в Москве (по данным государственного регистра больных сахарным диабетом). Эндокринология: новости; мнения; обучение. 2017;4(21):79–83. [Demidov N.A.; Kalashnikova M.F.; Pashkova E.Yu.; Antsiferov M.B. Features of the management of patients with type 2 diabetes mellitus older than 85 years in Moscow (according to the state register of patients with diabetes mellitus). Endocrinology: News; Opinions; Education. 2017;4(21):79–83. (In Russ.)].
  26. Анциферов М.Б.; Демидов Н.А.; Котешкова О.М. Использование современных сахароснижающих препаратов в терапии сахарного диабета 2 типа (по данным Московского сегмента Федерального регистра сахарного диабета). Эндокринология: новости; мнения; обучение. 2023;12(2):8–13. [Antsiferov M.B.; Demidov N.A.; Koteshkova O.M. The use of modern hypoglycemic drugs in the treatment of type 2 diabetes mellitus (according to the Moscow segment of the Federal Diabetes Registry). Endokrinologiya: novosti; mneniya; obuchenie (Endocrinology: News; Opinions; Training). 2023;12(2):8–13. (In Russ.)]. doi: 10.33029/2304-9529-2023-12-2-8-13.
  27. Herman G.A.; Bergman A.; Stevens C.; et al. Effect of single oral doses of sitagliptin; a dipeptidyl peptidase-4 inhibitor; on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–9.
  28. Miller S.; St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006;40(7–8):1336–43.
  29. Ким С.С.; Ким И.Ч.; Ли К.Д. и др. Эффективность и безопасность фиксированной комбинации ситаглиптина/метформина по сравнению с глимепиридом у пациентов с сахарным диабетом 2 типа: многоцентровое рандомизированное двойное слепое исследование. Эндокринология: новости; мнения; обучение. 2017;4:64–78. [Kim S.S.; Kim I.Ch.; Lee K.D.; et al. Efficacy and safety of the fixed combination of sitagliptin /metformin compared with glimepiride in patients with type 2 diabetes: a multicentre; randomized; double-blind study. Endokrino logia: Novosti; Mnenia; Obuchenie. 2017;4:64–78. (In Russ.)].
  30. Perez-Monteverde A.; Seck T.; Xu L.; et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011;65(9):930–8.
  31. Reasner C.; Olansky L.; Seck T.L.; et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diab Obes Metab.2011;13:644–52.
  32. Аметов А.С. Вилдаглиптин. Возможности оптимального контроля сахарного диабета 2 типа. Сахарный диабет. 2015;18(4):125–9. [Ametov A.S. Vildagliptin. Possibilities for optimal control of type 2 diabetes mellitus. Diab Mellit. 2015;18(4):125–9. (In Russ.)].
  33. Van Gaal L.; Hermans M.P.; Daci E.; et al. Effectiveness and tolerability of vildagliptin and the single pill combination of vildagliptin and metformin in ‘‘real-world’’ management of type2 diabetes mellitus: the G-FORCE Study. Diab Ther. 2019;10:965–79.
  34. Hermans M.; van Gaal L.; Rezette I.; et al. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). Prim Care Diab. 2016;10(6):425–33. doi: 10.1016/j.pcd.2016.05.008.
  35. Li-Nong Ji; Chang-Yu Pan; Ju-Ming Lu; et al. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc Diab. 2013;12:118.
  36. Mathieu C.; Barnett A.H.; Brath H.; et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;(67):947–56.
  37. Rosales R.; Abou Jaoude E.; Al-Arouj M.; et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diab Obes Metab. 2015;17(6):603–7.
  38. Демидов Н.А.; Котешкова О.М.; Балберова М.А.; Анциферов М.Б. Старт терапии сахарного диабета 2 типа с фиксированной комбинацией. метформин с вилдаглиптином или с глибенкламидом; есть ли разница? Фарматека. 2019;26(14):47–53. [Demidov N.A.; Koteshkova O.M.; Balberova M.A.; Antsiferov M.B. Start of therapy of type 2 diabetes mellitus with a fixed combination. Metformin with vildagliptin or glibenclamide; is there any difference? Farmateka. 2019;26(14):47–53. (In Russ.)].
  39. Демидов Н.А.; Анциферов М.Б.; Зилов А.В. Результаты клинического исследования эффективности и безопасности фиксированной комбинации вилдаглиптин+метформин в реальной клинической практике в России (исследование мастер). Сахарный диабет. 2020;23(6):514–22. [Demidov N.A.; Antsiferov M.B.; Zilov A.V. Results of a clinical study of the effectiveness and safety of the fixed combination of vildagliptin + metformin in real clinical practice in Russia (MASTER study). Diab Mellit. 2020;23(6):514–22. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies